As the sense of crisis regarding COVID-19 infection is decreasing, attention is being paid to whether Paxlovid, a treatment drug, can successfully be registered for insurance benefits. Pfizer Korea is currently proceeding with the registration process for Paxlovid, which has been approved as an oral treatment for COVID-19, with the goal of listing it for insurance benefits in the first half of next year. The government announced that it will pursue the registration of Paxlovid insurance benefits within the first half of 2024 in accordance with the plan to ease the COVID-19 crisis level adjustment roadmap.

This measure is due to the fact that Paxlovid, which is currently supplied free of charge, is abou